2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T679,There are no US Food and Drug Administration-approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient-reported outcome measures and mechanistic quantification allow RP-related pain characterization. The rationale for this narrative review is current RP treatment guidelines that focus on vasodilation. The question of why there are limitations to RP treatment in the United States is addressed through a comprehensive search strategy of published RP treatment guidelines up until September 1, 2025. Search databases included Medline (PubMed), Embase, and Scopus for the index terms "Raynaud's phenomenon treatment guidelines." If a society guideline was updated, only the most recent was included. Eligibility, data extraction, risk of bias, and quality assessment were subject to review by two independent reviewers, with a third reviewer resolving discrepancies. US-specific considerations of published guidelines are reviewed. A total of 118 published articles were identified by the search terms "Raynaud's phenomenon treatment guidelines," and 27 abstracts were reviewed. Four articles published as RP treatment recommendations or guidelines were reviewed for full content. Pain management for RP is not included in guideline-based care. There are advances in outcome measures for quantifying pain now available for RP clinical trials. Large US-based registries for systemic sclerosis using patient-reported outcomes can allow serial data collection on RP and RP-related digital lesions to provide real-world data on medication efficacy for pain relief.31:Tabe, Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization. The rationale for this narrative review is current RP treatment guidelines that focus on vasodilation. Methods The question of why there are limitations to RP treatment in the United States is addressed through a comprehensive search strategy of published RP treatment guidelines up until September 1, 2025. Search databases included Medline (PubMed), Embase, and Scopus for the index terms “Raynaud's phenomenon treatment guidelines.” If a society guideline was updated, only the most recent was included. Eligibility, data extraction, risk of bias, and quality assessment were subject to review by two independent reviewers, with a third reviewer resolving discrepancies. US‐specific considerations of published guidelines are reviewed. Results A total of 118 published articles were identified by the search terms “Raynaud's phenomenon treatment guidelines,” and 27 abstracts were reviewed. Four articles published as RP treatment recommendations or guidelines were reviewed for full content. Pain management for RP is not included in guideline‐based care. Conclusion There are advances in outcome measures for quantifying pain now available for RP clinical trials. Large US‐based registries for systemic sclerosis using patient‐reported outcomes can allow serial data collection on RP and RP‐related digital lesions to provide real‐world data on medication efficacy for pain relief.

image

25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Raynaud Phenomenon: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Raynaud Phenomenon (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Raynaud%20Phenomenon\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Raynaud Phenomenon\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Raynaud%20Phenomenon\"}]}}"}}]],["$","$L2f",null,{"title":"Raynaud Phenomenon: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Raynaud Phenomenon with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1002/acr.80068","pmid":"42007790","title":"Artificial Intelligence in Systemic Sclerosis: Clinical Applications, Challenges, and Future Directions","journal_title":"Arthritis Care & Research","journal_issn":"2151-464X","published_at":"2026-05-07T00:00:00.000Z","url":"https://doi.org/10.1002/acr.80068","source_score":12,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-28T13:24:19.652Z","updated_at":"2026-05-28T13:24:19.652Z","tags":[{"paper_doi":"10.1002/acr.80068","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"condition","value":"Interstitial Lung Disease","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"condition","value":"Raynaud Phenomenon","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"condition","value":"Systemic Sclerosis","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"modality","value":"Artificial Intelligence","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"modality","value":"Deep Learning","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"modality","value":"Machine Learning","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"modality","value":"Radiomics","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"warning","value":"Full text was inaccessible; all structured data extracted from the abstract only — specific study counts, patient numbers, and performance metrics may be available in the full paper.","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"warning","value":"No sample size is reported as this is a narrative review aggregating multiple studies; individual study sizes are not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1002/acr.80068","tag_type":"warning","value":"The review is narrative rather than systematic, which limits conclusions about overall evidence quality across included studies.","value_numeric":null}],"summaries":{"what_studied":"This narrative review evaluates current AI applications — including machine learning, deep learning, and radiomics — in systemic sclerosis (SSc), covering disease phenotyping, imaging quantification (HRCT, nailfold capillaroscopy, ultrasound), skin assessment, and risk stratification.","key_result":"AI-driven HRCT analysis enables automated fibrosis segmentation and radiomic risk modeling in SSc-ILD; computer vision applied to nailfold capillaroscopy achieves expert-level agreement for microvascular staging; AI-assisted skin imaging tools provide reproducible quantification of dermal remodeling — but most applications remain exploratory, based on small or single-center datasets with limited external validation.","limitations":"- Most studies use small or single-center datasets, limiting generalizability.\n- Data heterogeneity, annotation burden, and 'small data' constraints of rare diseases impede clinical translation.\n- No external validation reported for the majority of reviewed applications.","practice_takeaway":"AI tools for SSc — especially in ILD imaging and capillaroscopy — show promise but are not yet ready for routine clinical use. Clinicians should watch for multicenter-validated tools before adopting AI-driven SSc assessment in practice."}},{"doi":"10.1002/acr.25660","pmid":"40999744","title":"Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States","journal_title":"Arthritis Care & Research","journal_issn":"2151-464X","published_at":"2025-09-26T00:00:00.000Z","url":"https://doi.org/10.1002/acr.25660","source_score":23,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-14","doi":"10.1002/acr.25660","days":"30","issn":"2151-464X","rank":"7","field":"Clinical Medicine","score":"23","category":"Rheumatology","categories":["Rheumatology"],"_categories":["Rheumatology"]},"pubmed":{"doi":"10.1002/acr.25660","title":"Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue-Related Raynaud Phenomenon in the United States.","journal":"Arthritis care & research","methods":"","results":"A total of 118 published articles were identified by the search terms \"Raynaud's phenomenon treatment guidelines,\" and 27 abstracts were reviewed. Four articles published as RP treatment recommendations or guidelines were reviewed for full content. Pain management for RP is not included in guideline-based care.","abstract":"$30","keywords":[],"pubmed_id":"40999744","conclusions":"There are advances in outcome measures for quantifying pain now available for RP clinical trials. Large US-based registries for systemic sclerosis using patient-reported outcomes can allow serial data collection on RP and RP-related digital lesions to provide real-world data on medication efficacy for pain relief.","publication_date":"2025-09-26T00:00:00"},"crossref":{"DOI":"10.1002/acr.25660","URL":"https://doi.org/10.1002/acr.25660","ISSN":["2151-464X","2151-4658"],"link":[{"URL":"https://acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/acr.25660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States"],"author":[{"given":"Tracy M.","family":"Frech","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center and Tennessee Valley Healthcare System Nashivile Tennessee"}]},{"given":"Charles G.","family":"Frech","sequence":"additional","affiliation":[{"name":"Vanderbilt University Nashville Tennessee"}]},{"given":"W. David","family":"Merryman","sequence":"additional","affiliation":[{"name":"Vanderbilt University Nashville Tennessee"}]},{"given":"Andrew","family":"Sternlicht","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine Boston Massachusetts"}]},{"given":"Justin","family":"Baba","sequence":"additional","affiliation":[{"name":"Vanderbilt University Nashville Tennessee"}]}],"funder":[{"id":[{"id":"10.13039/100000738","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000738","name":"U.S. Department of Veterans Affairs","award":["5I01CX002111‐03"],"award-info":[{"award-number":["5I01CX002111‐03"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,12,12]]},"member":"311","prefix":"10.1002","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-09-26T06:19:26Z","timestamp":1758867566000,"date-parts":[[2025,9,26]]},"indexed":{"date-time":"2025-12-17T04:47:51Z","timestamp":1765946871768,"date-parts":[[2025,12,17]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000,"date-parts":[[2025,12,12]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.25660"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-07-08"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-16"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-12-12"}],"deposited":{"date-time":"2025-12-17T04:45:48Z","timestamp":1765946748000,"date-parts":[[2025,12,17]]},"issn-type":[{"type":"print","value":"2151-464X"},{"type":"electronic","value":"2151-4658"}],"published":{"date-parts":[[2025,12,12]]},"publisher":"Wiley","reference":[{"DOI":"10.1136/bmjopen-2014-006389","key":"e_1_2_3_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1024/0301-1526/a000661","key":"e_1_2_3_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.berh.2023.101849","key":"e_1_2_3_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.reuma.2012.02.006","key":"e_1_2_3_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.38098","key":"e_1_2_3_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.autrev.2020.102458","key":"e_1_2_3_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3899/jrheum.190565","key":"e_1_2_3_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_3_9_1","year":"2022","issue":"10","author":"Mo YQ","volume":"61","first-page":"1119","unstructured":null,"article-title":"Standardized diagnosis and treatment of undifferentiated connective tissue disease and mixed connective tissue disease. Article in Chinese","journal-title":"Zhonghua Nei Ke Za Zhi","doi-asserted-by":null},{"DOI":"10.1136/ard-2024-226430","key":"e_1_2_3_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.40560","key":"e_1_2_3_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/kew224","key":"e_1_2_3_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2021.7934","key":"e_1_2_3_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_3_14_1","year":"2022","issue":"1","author":"Nawaz I","volume":"14","first-page":null,"unstructured":null,"article-title":"Raynaud's phenomenon: reviewing the pathophysiology and management strategies","journal-title":"Cureus","doi-asserted-by":null},{"DOI":"10.1093/rheumatology/keaf073","key":"e_1_2_3_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/keae197","key":"e_1_2_3_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_3_17_1","year":"2016","issue":"2","author":"Ennis H","volume":null,"first-page":null,"unstructured":null,"article-title":"Calcium channel blockers for primary Raynaud's phenomenon","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_3_18_1","year":"2017","issue":"12","author":"Rirash F","volume":null,"first-page":null,"unstructured":null,"article-title":"Calcium channel blockers for primary and secondary Raynaud's phenomenon","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_3_19_1","year":"2017","issue":"4","author":"Pauling JD","volume":"35","first-page":"184","unstructured":null,"article-title":"Patient participation in patient‐reported outcome instrument development in systemic sclerosis","journal-title":"Clin Exp Rheumatol","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_3_20_1","year":"2007","issue":"5","author":"Furst D","volume":"34","first-page":"1194","unstructured":null,"article-title":"Systemic sclerosis ‐ continuing progress in developing clinical measures of response","journal-title":"J Rheumatol","doi-asserted-by":null},{"DOI":"10.1002/art.10486","key":"e_1_2_3_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/37.9.952","key":"e_1_2_3_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","key":"e_1_2_3_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2665-9913(20)30030-8","key":"e_1_2_3_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/acr.23729","key":"e_1_2_3_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3899/jrheum.201612","key":"e_1_2_3_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3899/jrheum.180818","key":"e_1_2_3_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2665-9913(24)00189-9","key":"e_1_2_3_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/kead371","key":"e_1_2_3_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/acr.25038","key":"e_1_2_3_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00296-016-3483-6","key":"e_1_2_3_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.autrev.2017.11.036","key":"e_1_2_3_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaut.2014.01.020","key":"e_1_2_3_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm11092490","key":"e_1_2_3_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/rap/rkad022","key":"e_1_2_3_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/nrrheum.2014.195","key":"e_1_2_3_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCRESAHA.123.323299","key":"e_1_2_3_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_3_38_1","year":"1989","issue":"1","author":"Elfont RM","volume":"256","first-page":"R224","unstructured":null,"article-title":"Adrenergic receptors on cerebral microvessels: pericyte contribution","journal-title":"Am J Physiol","doi-asserted-by":null},{"DOI":"10.1159/000159237","key":"e_1_2_3_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10067-014-2834-5","key":"e_1_2_3_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_3_41_1","year":"2017","issue":"4","author":"Machin DR","volume":"35","first-page":"167","unstructured":null,"article-title":"Acute oral tetrahydrobiopterin administration ameliorates endothelial dysfunction in systemic sclerosis","journal-title":"Clin Exp Rheumatol","doi-asserted-by":null},{"DOI":"10.3389/fmed.2021.791689","key":"e_1_2_3_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fcvm.2021.649630","key":"e_1_2_3_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.59556/japi.72.0516","key":"e_1_2_3_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_3_45_1","year":"2024","issue":"9","author":"Sternlicht A","volume":"76","first-page":null,"unstructured":null,"article-title":"AISA 021, a novel calcium channel antagonist in development for Raynaud's & systemic sclerosis, has antagonistic activity at sodium channel targets for pain relief and treats scleroderma pain better than current calcium channel blockers in a phase 2A study [abstract]","journal-title":"Arthritis Rheumatol","doi-asserted-by":null},{"DOI":"10.1177/2397198318823951","key":"e_1_2_3_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/acel.14075","key":"e_1_2_3_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4155/fmc-2023-0101","key":"e_1_2_3_48_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2024.1407871","key":"e_1_2_3_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jbspin.2021.105309","key":"e_1_2_3_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/exd.14193","key":"e_1_2_3_51_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/SAP.0000000000003603","key":"e_1_2_3_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/srep09072","key":"e_1_2_3_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/papr.13421","key":"e_1_2_3_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.21.02285","key":"e_1_2_3_55_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s41927-021-00209-z","key":"e_1_2_3_56_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10067-019-04792-y","key":"e_1_2_3_57_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1002/acr.25660"],"article-number":"acr.25660","content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Arthritis Care & Research"],"reference-count":56,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,12]]},"references-count":56,"short-container-title":["Arthritis Care & Research"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1002/acr.25660","is_oa":true,"title":"Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States","updated":"2025-12-15T00:25:58+00:00","published_date":"2025-09-26","best_oa_location":{"url":"https://doi.org/10.1002/acr.25660","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1002/acr.25660"}}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-11T11:19:33.869Z","tags":[{"paper_doi":"10.1002/acr.25660","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1002/acr.25660","tag_type":"condition","value":"Raynaud Phenomenon","value_numeric":null},{"paper_doi":"10.1002/acr.25660","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/acr.25660","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1002/acr.25660","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1002/acr.25660","tag_type":"warning","value":"Counts refer to guideline documents, not patients or trials.","value_numeric":null},{"paper_doi":"10.1002/acr.25660","tag_type":"warning","value":"Design classified as a narrative review per authors; not a systematic review or meta-analysis.","value_numeric":null},{"paper_doi":"10.1002/acr.25660","tag_type":"warning","value":"Search strategy used a single index term, which may miss differently indexed guidance.","value_numeric":null}],"summaries":{"what_studied":"A narrative review of US-relevant Raynaud phenomenon treatment guidelines through September 1, 2025, using Medline, Embase, and Scopus with the index term “Raynaud’s phenomenon treatment guidelines,” with dual independent review and adjudication.","key_result":"From 118 records, 27 abstracts were screened and 4 guideline articles were reviewed in full; none included pain management in guideline-based care.","limitations":"Narrative review of guidelines rather than patient-level studies or trials; only the most recent version of each society guideline was included; conclusions rest on just 4 guidelines.","practice_takeaway":"Current US guidelines for Raynaud phenomenon do not address pain. Recognize this gap and document RP pain with available patient-reported outcome measures, and consider participation in trials or registries that use these tools."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Raynaud Phenomenon"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Raynaud Phenomenon"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Raynaud Phenomenon"}}}]]

Papers